On Monday, Moderna announced that its experimental combination vaccine for flu and COVID-19 - mRNA-1083 showed positive results in a Phase 3 clinical trial. The combined vaccine had a stronger immune response compared to the currently available individual vaccines. Moderna is planning to present the full results of phase 3 trials at an upcoming medical conference and discuss the next steps with regulators.

Source: MedCity News - June 10, 2024